Literature DB >> 18307564

Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia.

Evelio D Perez-Albuerne1, Mary Eapen, John Klein, Thomas J Gross, Jeffery M Lipton, K Scott Baker, Anne Woolfrey, Naynesh Kamani.   

Abstract

For children with severe aplastic anemia (SAA) who fail immunosuppressive therapy and lack a human leucocyte antigen (HLA)-matched sibling donor, unrelated donors provide a source of hematopoietic stem cells. Data from 195 children with acquired SAA who underwent unrelated donor transplantation between 1989 and 2003 were analyzed. Neutrophil recovery (86% at day-28) was higher with total body irradiation-containing conditioning regimen and in younger recipients (aged < or =16 years) receiving grafts from older donors (aged >40 years). Recovery was lower after mismatched transplants and transplantations prior to 1997. Mortality rates were higher after mismatched transplants, in recipients with a poor performance score, and when the interval between diagnosis and transplantation was longer than 4 years. When restricted to donor-recipient pairs with allele-level HLA typing (8-loci; n = 118), mortality rates were also higher after mismatched transplants and older recipients receiving grafts from older donors; 5-year probabilities of overall survival after HLA-A, -B, -C, -DRB1 matched and mismatched transplants adjusted for donor and recipient age were 57% and 39%, respectively (P = 0.008). The data suggest that unrelated donor transplantation is an acceptable alternative for children; early referral for transplantation and identification of an HLA-matched (allele-level) donor offers the best outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307564      PMCID: PMC3164958          DOI: 10.1111/j.1365-2141.2008.07030.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

Review 1.  Treatment of aplastic anemia.

Authors:  T P Loughran; R Storb
Journal:  Hematol Oncol Clin North Am       Date:  1990-06       Impact factor: 3.722

2.  Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults.

Authors:  D Margolis; B Camitta; D Pietryga; C Keever-Taylor; L A Baxter-Lowe; K Pierce; M J Kupst; J French; R Truitt; C Lawton; K Murray; F Garbrecht; N Flomenberg; J Casper
Journal:  Br J Haematol       Date:  1996-07       Impact factor: 6.998

3.  Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT).

Authors:  M M de Planque; A Bacigalupo; A Würsch; J M Hows; A Devergie; N Frickhofen; A Brand; C Nissen
Journal:  Br J Haematol       Date:  1989-09       Impact factor: 6.998

4.  BMT for severe aplastic anemia using cyclosporine.

Authors:  W S May; L L Sensenbrenner; W H Burns; R Ambinder; M P Carroll; C A Griffin; R J Jones; C B Miller; E D Mellits; G B Vogelsang
Journal:  Bone Marrow Transplant       Date:  1993-06       Impact factor: 5.483

Review 5.  Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results.

Authors:  B M Camitta; K Doney
Journal:  Am J Pediatr Hematol Oncol       Date:  1990

6.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.

Authors:  R Storb; R Etzioni; C Anasetti; F R Appelbaum; C D Buckner; W Bensinger; E Bryant; R Clift; H J Deeg; K Doney
Journal:  Blood       Date:  1994-08-01       Impact factor: 22.113

7.  Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor.

Authors:  N Bunin; A Leahey; N Kamani; C August
Journal:  J Pediatr Hematol Oncol       Date:  1996-02       Impact factor: 1.289

8.  Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party.

Authors:  H Schrezenmeier; P Marin; A Raghavachar; S McCann; J Hows; E Gluckman; C Nissen; E T van't Veer-Korthof; P Ljungman; W Hinterberger
Journal:  Br J Haematol       Date:  1993-10       Impact factor: 6.998

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.

Authors:  G Socié; M Henry-Amar; A Bacigalupo; J Hows; A Tichelli; P Ljungman; S R McCann; N Frickhofen; E Van't Veer-Korthof; E Gluckman
Journal:  N Engl J Med       Date:  1993-10-14       Impact factor: 91.245

View more
  15 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long-term overall survival after transplantation with related donors compared to unrelated donors.

Authors:  B K Mortensen; N Jacobsen; C Heilmann; H Sengeløv
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

Review 3.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

4.  Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia.

Authors:  Shahinaz M Gadalla; Tao Wang; Michael Haagenson; Stephen R Spellman; Stephanie J Lee; Kirsten M Williams; Jason Y Wong; Immaculata De Vivo; Sharon A Savage
Journal:  JAMA       Date:  2015-02-10       Impact factor: 56.272

5.  Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.

Authors:  Michael J Eckrich; Kwang-Woo Ahn; Richard E Champlin; Peter Coccia; Kamar Godder; John Horan; David Margolis; H Joachim Deeg; Mary Eapen
Journal:  Am J Hematol       Date:  2013-11-15       Impact factor: 10.047

6.  Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children.

Authors:  Michaël Philippe; Emilie Hénin; Yves Bertrand; Dominique Plantaz; Sylvain Goutelle; Nathalie Bleyzac
Journal:  AAPS J       Date:  2015-05-15       Impact factor: 4.009

7.  Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases.

Authors:  Mark Leick; Bradley Hunter; Zachariah DeFilipp; Bimalangshu R Dey; Areej El-Jawahri; Matthew Frigault; Steven McAfee; Thomas R Spitzer; Paul O'Donnell; Yi-Bin Chen
Journal:  Bone Marrow Transplant       Date:  2019-10-24       Impact factor: 5.483

8.  Effect of Recipient Age and Stem Cell Source on the Association between Donor Telomere Length and Survival after Allogeneic Unrelated Hematopoietic Cell Transplantation for Severe Aplastic Anemia.

Authors:  Shahinaz M Gadalla; Tao Wang; Casey Dagnall; Michael Haagenson; Stephen R Spellman; Belynda Hicks; Kristine Jones; Hormuzd A Katki; Stephanie J Lee; Sharon A Savage
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-15       Impact factor: 5.742

9.  Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia.

Authors:  K Kudo; H Muramatsu; N Yoshida; R Kobayashi; H Yabe; K Tabuchi; K Kato; K Koh; Y Takahashi; Y Hashii; Y Kawano; M Inoue; Y Cho; H Sakamaki; K Kawa; K Kato; R Suzuki; S Kojima
Journal:  Bone Marrow Transplant       Date:  2015-06-29       Impact factor: 5.483

Review 10.  Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.

Authors:  Frank Peinemann; Ulrich Grouven; Nicolaus Kröger; Max Pittler; Beate Zschorlich; Stefan Lange
Journal:  Haematologica       Date:  2009-07-31       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.